Skin Cutaneous Melanoma: Correlation between copy number variations of arm-level result and selected clinical features
(All_Primary cohort)
Maintained by TCGA GDAC Team (Broad Institute/MD Anderson Cancer Center/Harvard Medical School)
Overview
Introduction

This pipeline computes the correlation between significant arm-level copy number variations (cnvs) and selected clinical features.

Summary

Testing the association between copy number variation 38 arm-level results and 7 clinical features across 29 patients, no significant finding detected with Q value < 0.25.

  • No arm-level cnvs related to clinical features.

Results
Overview of the results

Table 1.  Get Full Table Overview of the association between significant copy number variation of 38 arm-level results and 7 clinical features. Shown in the table are P values (Q values). Thresholded by Q value < 0.25, no significant finding detected.

Clinical
Features
Time
to
Death
AGE PRIMARY
SITE
OF
DISEASE
GENDER LYMPH
NODE
METASTASIS
TUMOR
STAGECODE
NEOPLASM
DISEASESTAGE
nCNV (%) nWild-Type logrank test t-test Fisher's exact test Fisher's exact test Chi-square test t-test Chi-square test
1p gain 4 (14%) 25 0.162
(1.00)
0.549
(1.00)
0.467
(1.00)
1
(1.00)
0.0369
(1.00)
0.3
(1.00)
1q gain 6 (21%) 23 0.929
(1.00)
0.725
(1.00)
0.18
(1.00)
1
(1.00)
0.0559
(1.00)
0.269
(1.00)
5p gain 4 (14%) 25 1
(1.00)
0.726
(1.00)
1
(1.00)
0.076
(1.00)
0.775
(1.00)
0.334
(1.00)
6p gain 8 (28%) 21 0.432
(1.00)
0.965
(1.00)
0.748
(1.00)
0.371
(1.00)
0.419
(1.00)
0.524
(1.00)
6q gain 3 (10%) 26 0.367
(1.00)
0.6
(1.00)
1
(1.00)
0.532
(1.00)
0.127
(1.00)
0.191
(1.00)
7p gain 13 (45%) 16 0.722
(1.00)
0.832
(1.00)
1
(1.00)
0.13
(1.00)
0.366
(1.00)
0.497
(1.00)
7q gain 13 (45%) 16 0.722
(1.00)
0.832
(1.00)
1
(1.00)
0.13
(1.00)
0.366
(1.00)
0.497
(1.00)
8p gain 5 (17%) 24 0.201
(1.00)
0.81
(1.00)
0.127
(1.00)
1
(1.00)
0.0839
(1.00)
0.202
(1.00)
8q gain 9 (31%) 20 0.193
(1.00)
0.301
(1.00)
0.364
(1.00)
0.396
(1.00)
0.613
(1.00)
0.73
(1.00)
13q gain 3 (10%) 26 1
(1.00)
0.948
(1.00)
1
(1.00)
0.532
(1.00)
0.419
(1.00)
0.865
(1.00)
18p gain 3 (10%) 26 0.371
(1.00)
1
(1.00)
18q gain 3 (10%) 26 0.371
(1.00)
1
(1.00)
20p gain 4 (14%) 25 0.0917
(1.00)
1
(1.00)
0.28
(1.00)
0.299
(1.00)
0.3
(1.00)
20q gain 5 (17%) 24 0.0173
(1.00)
1
(1.00)
1
(1.00)
0.419
(1.00)
0.121
(1.00)
22q gain 3 (10%) 26 0.133
(1.00)
1
(1.00)
1
(1.00)
0.893
(1.00)
0.191
(1.00)
2p loss 4 (14%) 25 0.705
(1.00)
0.633
(1.00)
0.08
(1.00)
1
(1.00)
0.0167
(1.00)
0.148
(1.00)
2q loss 3 (10%) 26 0.705
(1.00)
0.633
(1.00)
0.371
(1.00)
0.532
(1.00)
0.0501
(1.00)
4p loss 4 (14%) 25 1
(1.00)
0.786
(1.00)
1
(1.00)
0.28
(1.00)
0.889
(1.00)
0.334
(1.00)
4q loss 6 (21%) 23 1
(1.00)
0.985
(1.00)
1
(1.00)
0.633
(1.00)
0.47
(1.00)
0.358
(1.00)
5q loss 4 (14%) 25 0.682
(1.00)
0.486
(1.00)
0.467
(1.00)
0.28
(1.00)
0.219
(1.00)
0.191
(1.00)
6q loss 8 (28%) 21 0.395
(1.00)
0.569
(1.00)
0.748
(1.00)
1
(1.00)
0.975
(1.00)
0.739
(1.00)
8p loss 6 (21%) 23 0.395
(1.00)
0.932
(1.00)
1
(1.00)
0.633
(1.00)
0.47
(1.00)
0.848
(1.00)
8q loss 3 (10%) 26 1
(1.00)
0.312
(1.00)
1
(1.00)
1
(1.00)
0.893
(1.00)
0.911
(1.00)
9p loss 17 (59%) 12 0.231
(1.00)
0.412
(1.00)
0.147
(1.00)
0.422
(1.00)
0.582
(1.00)
0.637
(1.00)
9q loss 9 (31%) 20 0.682
(1.00)
0.679
(1.00)
1
(1.00)
0.675
(1.00)
0.94
(1.00)
0.0738
(1.00)
10p loss 13 (45%) 16 0.619
(1.00)
0.328
(1.00)
0.0301
(1.00)
1
(1.00)
0.346
(1.00)
0.269
(1.00)
10q loss 15 (52%) 14 0.619
(1.00)
0.259
(1.00)
0.0996
(1.00)
1
(1.00)
0.652
(1.00)
0.497
(1.00)
11p loss 7 (24%) 22 1
(1.00)
0.583
(1.00)
0.238
(1.00)
1
(1.00)
0.325
(1.00)
0.05
(1.00)
11q loss 8 (28%) 21 1
(1.00)
0.694
(1.00)
0.3
(1.00)
0.675
(1.00)
0.489
(1.00)
0.104
(1.00)
12p loss 3 (10%) 26 0.705
(1.00)
0.633
(1.00)
0.371
(1.00)
1
(1.00)
0.127
(1.00)
12q loss 5 (17%) 24 0.705
(1.00)
0.689
(1.00)
0.553
(1.00)
0.633
(1.00)
0.419
(1.00)
0.334
(1.00)
13q loss 5 (17%) 24 0.201
(1.00)
0.00425
(0.898)
1
(1.00)
0.633
(1.00)
0.419
(1.00)
0.525
(1.00)
14q loss 4 (14%) 25 1
(1.00)
0.56
(1.00)
1
(1.00)
0.568
(1.00)
0.889
(1.00)
0.958
(1.00)
16q loss 8 (28%) 21 0.00815
(1.00)
0.454
(1.00)
0.748
(1.00)
1
(1.00)
0.644
(1.00)
0.883
(1.00)
17p loss 4 (14%) 25 1
(1.00)
0.609
(1.00)
1
(1.00)
1
(1.00)
0.775
(1.00)
0.807
(1.00)
18p loss 3 (10%) 26 0.912
(1.00)
0.371
(1.00)
1
(1.00)
0.893
(1.00)
19q loss 3 (10%) 26 1
(1.00)
0.532
(1.00)
0.893
(1.00)
0.911
(1.00)
21q loss 3 (10%) 26 0.929
(1.00)
0.852
(1.00)
1
(1.00)
0.532
(1.00)
0.127
(1.00)
0.148
(1.00)
Methods & Data
Input
  • Mutation data file = broad_values_by_arm.mutsig.cluster.txt

  • Clinical data file = SKCM-All_Primary.clin.merged.picked.txt

  • Number of patients = 29

  • Number of significantly arm-level cnvs = 38

  • Number of selected clinical features = 7

  • Exclude genes that fewer than K tumors have mutations, K = 3

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

Student's t-test analysis

For continuous numerical clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the clinical values between tumors with and without gene mutations using 't.test' function in R

Fisher's exact test

For binary or multi-class clinical features (nominal or ordinal), two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Chi-square test

For multi-class clinical features (nominal or ordinal), Chi-square tests (Greenwood and Nikulin 1996) were used to estimate the P values using the 'chisq.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

References
[1] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)
[2] Lehmann and Romano, Testing Statistical Hypotheses (3E ed.), New York: Springer. ISBN 0387988645 (2005)
[3] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)
[4] Greenwood and Nikulin, A guide to chi-squared testing, Wiley, New York. ISBN 047155779X (1996)
[5] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)